Manara - Qatar Research Repository
Browse
DOCUMENT
10.1016_j.ajo.2024.03.019.pdf (827.9 kB)
DOCUMENT
supp_1-s2.0-S0002939424001211-mmc1.docx (7.53 kB)
1/0
2 files

Efficacy and Safety of Lotilaner Ophthalmic Solution (0.25%) for the Treatment of Demodex Blepharitis: A GRADE Assessed Systematic Review and Meta-Analysis of Observational & Experimental Studies

journal contribution
submitted on 2024-03-27, 08:23 and posted on 2024-03-27, 08:23 authored by Muhammad Talha, Mohammad Haris Ali, Eeshal Fatima, Arsalan Nadeem, Abdullah Ahmed, Abdulqadir J. Nashwan

Purpose

This review aims to assess the safety and efficacy of Lotilaner in the treatment of Demodex Blepharitis.

Design

Systematic Review and Meta-Analysis

Background

Demodex blepharitis is a common eye condition that arises from Demodex mites infestation within the hair follicles of eyelashes, resulting in detrimental effects. The disease affects a significant part of the general population, including general eye care patients and individuals diagnosed with blepharitis. Several treatments have been in use before the discovery of lotilaner, like tea tree oil, and antibiotics; however, they either have irritable effects or systemic adverse effects, respectively. Lotilaner, a novel ectoparasiticide, has been proposed as a treatment for patients grappling with Demodex blepharitis. We primarily aimed to assess the efficacy and safety of Lotilaner for the treatment of Demodex blepharitis.

Methods

An extensive search was conducted on PubMed, Cochrane Library, Scopus, and Google Scholar to find relevant literature till 31 July 2023 following the PRISMA guidelines. A total of 143 articles were retrieved by database searching, out of which 6 studies met the inclusion criteria and were included in the review. Four RCTs were included in the meta-analysis of mite eradication incidence. The review is registered with PROSPERO: CRD42023459997.

Results

Lotilaner is effective in eradicating Demodex mites in individuals suffering from Demodex blepharitis according to RR for the intervention versus the control group of 3.55 (95% CI: 2.87 ‒ 4.40, P < 0.00001, I2 = 0%). The meta-analysis of clinically meaningful collarette score revealed the summary RR for the intervention versus the control group was 3.15 (95% CI: 2.56 ‒ 3.89, P < 0.00001, I2 = 27%). In conclusion, the results of the included studies were comparable and consistent.

Conclusions

Our results indicated that Lotilaner is an effective, well-tolerated, and promising drug in treating patients with Demodex blepharitis. Lotilaner administration and cost-effectiveness should now be contemplated for the study population as these constituents have a vital impact on its treatment success.

Other Information

Published in: American Journal of Ophthalmology
License: http://creativecommons.org/licenses/by/4.0/
See article on publisher's website: https://dx.doi.org/10.1016/j.ajo.2024.03.019

Funding

Open Access funding provided by the Qatar National Library.

History

Language

  • English

Publisher

Elsevier

Publication Year

  • 2024

License statement

This Item is licensed under the Creative Commons Attribution 4.0 International License.

Institution affiliated with

  • Hamad Medical Corporation
  • Qatar University
  • Qatar University Health - QU
  • College of Health Sciences - QU HEALTH

Usage metrics

    Hamad Medical Corporation

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC